This Week's Pick
The pick below is the most recent weekly pick published on StockIceMan.com. Watch this page — a new pick will appear here each week.
| Weekly Stock Pick — November 17, 2026 | |
| Stock: | Ardelyx, Inc. |
|---|---|
| Ticker Symbol: | ARDX - Nasdaq - Biotechnology |
| Buy: | 3.00 to 3.40 |
| Sell: | 12.50 |
| Info: | Ardelyx, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes innovative medicines that meet significant unmet medical needs in the United States and internationally. The company has two commercial products approved in the United States, both built on its tenapanor franchise: IBSRELA, a minimally absorbed small molecule therapy for the treatment of adults with irritable bowel syndrome with constipation (IBS-C), which produced revenue of $96.3 million in the third quarter of 2026, up 23% year over year; and XPHOZAH, a phosphate absorption inhibitor indicated to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy, which produced revenue of $29.2 million, up 7% year over year. The company's pipeline includes the Phase 3 ACCEL trial of tenapanor for the treatment of chronic idiopathic constipation (CIC) in adults, which completed enrollment ahead of schedule with topline data expected in the second half of 2027, and RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx works with partners to develop and commercialize its products outside of the United States. Management has reiterated full-year 2026 revenue guidance of $350 to $370 million for IBSRELA and $110 to $120 million for XPHOZAH, carries a long-term target of $1 billion in annual IBSRELA revenue, and expects GAAP profitability in 2027. The company held $285.3 million in cash, cash equivalents and investments as of September 30, 2026. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts. |
| Financial Info: | For the quarter ended 9/30/2026, revenues increased 15.7% to $127.7 million compared to the same quarter in 2025, and increased 5.6% from the second quarter of 2026. Total product revenue increased 19% to $125.5 million compared to the same quarter in 2025. Net loss decreased 23.7% to $0.7 million compared to the same quarter in 2025. |
| Key Ratios: | Current Ratio: 3.45, Total Debt/Equity Ratio: 1.73; Trailing P/E: N/A; Forward P/E: 76.63, Price/Sales: 1.71, Price/Book: 4.87 |
| Share Info: | There are 251.37 million shares outstanding with 215.59 million shares in the trading float. Institutions own approximately 65.85% of the shares outstanding, and insiders own approximately 3.35%. Real-Time SEC Filings As of the most recent short interest report, there were 29.21 million shares short, representing 11.62% of the shares outstanding. |
| Articles: | Ardelyx Reports Third Quarter 2026 Financial Results and Provides Business Update Ardelyx price target lowered to $11 from $14 at BTIG |
StockIceMan.com is not affiliated with, nor receives any compensation from, any private or publicly traded companies. Please read the Disclaimer and do your own research before investing.